| Objective:Cultivate mesenchyma stem cells of the full-term childbirth embryo umbilical cord, explore the method of umbilical cord mesenchymal stem cells separation in vitro, proliferation, identification, and observe the efficacy in treating of systemic lupus erythematosus (SLE).Methods:Collect newborn umbilical cord under sterile conditions, culture mesenchymal stem cells after separation, take cells for flow cytometry checking. Select5cases of systemic lupus erythematosus (SLEDAI score≥9).In medical treatment on the basis of the proliferation of the intravenous training within6generations of umbilical cord mesenchymal stem cells, Clinical changes were evaluated before and after transplantation using the SLE Disease Activity Index (SLEDAI), and testing the24-hour proteinuria, kidney and liver function, immunoglobulin, complement in blood serum. Before and after treatment of UC-MSC testing the relative quantity of cytokine of CD86, IL-17c, IL-2, Foxp3, TGFb2, CTLA-4there are related of immunopathogenesis of systemic lupus erythematosus.Results:(1) After treatment serum complement C3, C4level was risen (P<0.05, before treatment mean value of serum complement C3is0.62g/L, after treatment mean value of serum complement C3is0.71g/L, before treatment mean value of serum complement C4is0.10g/L, after treatment mean value of serum complement C4is 0.12g/L)24hour proteinuria was decreased (P<0.05, before treatment mean value of proteinuria is5.14g/24h, after treatment mean value of proteinuria is3.87g/24h), SLE Disease Activity Index (SLEDAI) was decreased (P<0.05).After treatment serumalbumin was risen (P<0.05, before treatment mean value of serumalbumin is30.41g/L, after treatment mean value of serumalbumin is32.01g/L).(2) There is no serious adverse reactions and complications occurred in5cases of transplant patients after treatment.(3) After treatment the relative expression value of CD86and IL-2was decreased (P <0.05, Before treatment mean value of CD86is2.736, after treatment mean value of is9.216.Before treatment mean value of IL-2is7.2115, after treatment mean value of IL-2is8.3538). After treatment the relative expression value of Foxp3, TGFb2, CTLA-4was risen, IL-17c was decreased,but without statistical significance.Conclusion:(1) Treatment of systemic lupus erythematosus by human umbilical cord mesenchymal stem cells can increase patient's serum complement C3, C4and serumalbumin, and improve clinical symptoms, decreased24hour proteinuria and SLE Disease Activity Index and improve clinical symptoms. Reduce kidney damage.(2) Human umbilical cord mesenchymal stem cell transplantation in patients with systemic lupus erythematosus is safe.(3)Umbilical cord mesenchymal stem cell transplantation therapy in patients after of immune regulation, to all sorts of immune cells have immune adjustment effect. |
PDF Full Text Request